<p>Our team is investigating the utility of outer membrane vesicles (OMVs) in the delivery of the Cas9-complex. All Gram-negative bacteria produce OMVs and use them to deliver toxins, communicate with other bacteria, mediate membrane composition, and extract materials such as metal ions from their environment. OMVs have been successfully engineered to carry heterologous proteins<a href="#_msocom_1" name="_msoanchor_1" id="_msoanchor_1"><sup>1</sup></a>, which makes them an attractive candidate for systems that require the delivery of a functional protein or complex to recipient cells. </p>
<p>Our team is investigating the utility of outer membrane vesicles (OMVs) in the delivery of the Cas9-complex. All Gram-negative bacteria produce OMVs and use them to deliver toxins, communicate with other bacteria, mediate membrane composition, and extract materials such as metal ions from their environment. OMVs have been successfully engineered to carry heterologous proteins<a href="#_msocom_1" name="_msoanchor_1" id="_msoanchor_1"><sup>1</sup></a>, which makes them an attractive candidate for systems that require the delivery of a functional protein or complex to recipient cells. </p>
<p>One such system is the application of CRISPR-Cas9 to treating antibiotic-resistant bacterial infections. At the moment the most effective methods of delivering Cas9 to target cells are either limited to DNA delivery (bacteriophage delivery<a href="#_msocom_2" name="_msoanchor_2" id="_msoanchor_2"><sup>2</sup></a> and hydrodynamic injection<a href="#_msocom_3" name="_msoanchor_3" id="_msoanchor_3"><sup>3</sup></a>) or require extensive vector engineering in order to facilitate controlled delivery and uptake (lipid-mediated transfection<a href="#_msocom_4" name="_msoanchor_4" id="_msoanchor_4"><sup>4</sup></a>).</p>
<p>One such system is the application of CRISPR-Cas9 to treating antibiotic-resistant bacterial infections. At the moment the most effective methods of delivering Cas9 to target cells are either limited to DNA delivery (bacteriophage delivery<a href="#_msocom_2" name="_msoanchor_2" id="_msoanchor_2"><sup>2</sup></a> and hydrodynamic injection<a href="#_msocom_3" name="_msoanchor_3" id="_msoanchor_3"><sup>3</sup></a>) or require extensive vector engineering in order to facilitate controlled delivery and uptake (lipid-mediated transfection<a href="#_msocom_4" name="_msoanchor_4" id="_msoanchor_4"><sup>4</sup></a>).</p>
−
<p>We hope to use signal peptides and protein fusions to direct Cas9 protein into OMVs so that the functional complex can be delivered to and act on the resistance genes in antibiotic-resistant bacteria without extensive lipid modification to facilitate uptake.</p></article>
+
<p>We hope to use signal peptides and protein fusions to direct Cas9 protein into OMVs so that the functional complex can be delivered to and act on the resistance genes in antibiotic-resistant bacteria without extensive lipid modification to facilitate uptake. With sufficient further development, CRISPR Capsules could be used in conjunction with traditional antibiotics to allow treatment of resistant infections.</p></article>
<ul class="ch-grid">
<ul class="ch-grid">
<li>
<li>
Revision as of 06:15, 16 October 2016
Northwestern
Home
What areCRISPR Capsules?
Our team is investigating the utility of outer membrane vesicles (OMVs) in the delivery of the Cas9-complex. All Gram-negative bacteria produce OMVs and use them to deliver toxins, communicate with other bacteria, mediate membrane composition, and extract materials such as metal ions from their environment. OMVs have been successfully engineered to carry heterologous proteins1, which makes them an attractive candidate for systems that require the delivery of a functional protein or complex to recipient cells.
One such system is the application of CRISPR-Cas9 to treating antibiotic-resistant bacterial infections. At the moment the most effective methods of delivering Cas9 to target cells are either limited to DNA delivery (bacteriophage delivery2 and hydrodynamic injection3) or require extensive vector engineering in order to facilitate controlled delivery and uptake (lipid-mediated transfection4).
We hope to use signal peptides and protein fusions to direct Cas9 protein into OMVs so that the functional complex can be delivered to and act on the resistance genes in antibiotic-resistant bacteria without extensive lipid modification to facilitate uptake. With sufficient further development, CRISPR Capsules could be used in conjunction with traditional antibiotics to allow treatment of resistant infections.
